GH
Guardant Health, Inc.
170.77
2 x 157.62
2 x 182.02
bid
ask
+
20.74
13.82%
2 @ 04:00 PM
171.88 +1.11 (0.65%)
Ytd67.19%
1y236.76%
156.16
day range
172.60
40.35
52 week range
172.61
Open160.75Prev Close150.03Low156.16High172.60Mkt Cap22.64B
Vol6.66MAvg Vol2.67MEPS-3.40P/EN/AForward P/E-435.81
Beta1.62Short Ratio5.33Inst. Own105.97%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning07-2950-d Avg115.33200-d Avg97.351yr Est144.42

GH News

UnitedHealth Group Now Covers Guardant Health's Shield Blood Test for Colorectal Cancer Screening
businesswire.com
UnitedHealth Group Now Covers Guardant Health's Shield Blood Test for Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

benzinga.com
BTIG Maintains Buy on Guardant Health, Raises Price Target to $190

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price t

State Street SPDR Small Cap ETF Outpaces iShares on Returns
fool.com
State Street SPDR Small Cap ETF Outpaces iShares on Returns

Explore how portfolio size and sector exposure differ between these two small-cap ETFs, each offerin

benzinga.com
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $160

Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the pr

benzinga.com
Bernstein Reinstates Outperform on Guardant Health, Announces $175 Price Target

Bernstein analyst Eve Burstein reinstates Guardant Health (NASDAQ:GH) with a Outperform and annou

benzinga.com
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $150

Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises

benzinga.com
RBC Capital Initiates Coverage On Guardant Health with Outperform Rating, Announces Price Target of

RBC Capital analyst Dan Leonard initiates coverage on Guardant Health (NASDAQ:GH) with a Outperfo

benzinga.com
Guardant Health Says FDA Approves Guardant360 CDx As Companion Diagnostic For Boehringer Ingelheim's

Blood-based liquid biopsy test enables identification of patients eligible for treatment with HERNEX

benzinga.com
Mizuho Maintains Outperform on Guardant Health, Raises Price Target to $175

Mizuho analyst Anthony Petrone maintains Guardant Health (NASDAQ:GH) with a Outperform and raises

benzinga.com
Goldman Sachs Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $165

Goldman Sachs analyst Evie Koslosky initiates coverage on Guardant Health (NASDAQ:GH) with a Buy

CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday
benzinga.com
CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, H

This Evercore ISI Group Analyst Turns Bullish; Here Are Top 2 Upgrades For Tuesday
benzinga.com
This Evercore ISI Group Analyst Turns Bullish; Here Are Top 2 Upgrades For Tuesday

Top Wall Street analysts upgraded GH to Outperform and raised price target to $160. Other analysts a

benzinga.com
Wolfe Research Assumes Guardant Health at Outperform, Announces Price Target of $150

Wolfe Research analyst Mike Polark assumes Guardant Health (NASDAQ:GH) with a Outperform rating a

benzinga.com
Evercore ISI Group Upgrades Guardant Health to Outperform, Raises Price Target to $160

Evercore ISI Group analyst Vijay Kumar upgrades Guardant Health (NASDAQ:GH) from In-Line to Outpe

benzinga.com
Guardant Health To Present 38 Abstracts, As Well As One Oral Presentation In Partnership With Pfizer

New performance data demonstrates validity of Guardant360 Liquid CDx as a comprehensive pan-cancer c

benzinga.com
BTIG Maintains Buy on Guardant Health, Raises Price Target to $160

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price t

benzinga.com
Guardant Health Says Its FDA-Approved Shield Blood Test Is Now Included In Updated American Cancer S

Updated ACS guideline offers Shield as a new choice for over 50 million eligible Americans who are n

benzinga.com
BTIG Maintains Buy on Guardant Health, Raises Price Target to $155

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price t

D-Wave, Dell, And IonQ Are Among Top 10 Large-Cap Gainers Last Week (May 18-May 22): Are the Others in Your Portfolio?
benzinga.com
D-Wave, Dell, And IonQ Are Among Top 10 Large-Cap Gainers Last Week (May 18-May 22): Are the Others

Quantum computing, AI and semiconductor-linked stocks dominated last week's large-cap gainers as

Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test
benzinga.com
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test

Guardant Health secured FDA approval for Guardant360 Liquid CDx, expanding blood-based cancer profil

benzinga.com
Guardant Health Announces FDA Approval Of The Company's Liquid CDx To Advance Blood-Based Comprehens

Guardant Health's new FDA-approved liquid biopsy integrates genomic and epigenomic insights to p

benzinga.com
JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $135

JP Morgan analyst Casey Woodring maintains Guardant Health (NASDAQ:GH) with a Overweight and rais

benzinga.com
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $120

Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises

benzinga.com
Evercore ISI Group Maintains In-Line on Guardant Health, Raises Price Target to $95

Evercore ISI Group analyst Daniel Markowitz maintains Guardant Health (NASDAQ:GH) with a In-Line

benzinga.com
Guardant Health Raises FY2026 Sales Guidance from $1.250B-$1.280B to $1.300B-$1.320B vs $1.271B Est

2026 GuidanceGuardant Health now expects full year 2026 revenue to be in the range of $1.30 to $1.32

benzinga.com
Guardant Health Q1 Adj. EPS $(0.45) Beats $(0.76) Estimate, Sales $301.665M Beat $279.198M Estimate

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.45) per share which beat the analyst co

Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy
benzinga.com
Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy

Pfizer and Arvinas secure FDA approval for VEPPANU (vepdegestrant), a first-of-its-kind treatment fo

benzinga.com
Guardant Health Announces FDA Approval Of The Guardant360 CDx Liquid Biopsy Test As A Companion Diag

VEPPANU, jointly developed by Arvinas, Inc. and Pfizer Inc., is approved for the treatment of adults

10 Health Care Stocks With Whale Alerts In Today's Session
benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session

benzinga.com
Guardant Health And Nuvalent Enter Strategic Collaboration For The Development And Potential Commerc

The collaboration reflects the growing importance of precision diagnostics in oncology drug developm

Why Is Guardant Health Stock Falling On Tuesday?
benzinga.com
Why Is Guardant Health Stock Falling On Tuesday?

FDA highlights concerns over camizestrant data, questioning PFS relevance, OS maturity, and benefit-

Cloudflare, ServiceNow, And Guardant Health Are Among Top 10 Large-Cap Losers Last Week (April 6-April 10): Are the Others in Your Portfolio?
benzinga.com
Cloudflare, ServiceNow, And Guardant Health Are Among Top 10 Large-Cap Losers Last Week (April 6-Apr

Macro concerns, AI competition, and analyst downgrades drove broad weekly losses across software and

benzinga.com
Evercore ISI Group Maintains In-Line on Guardant Health, Lowers Price Target to $90

Evercore ISI Group analyst Daniel Markowitz maintains Guardant Health (NASDAQ:GH) with a In-Line

benzinga.com
Guardant Health's InfinityAI Real-World Evidence Supports Japan Approval Of ENHERTU For HER2-Positiv

This milestone underscores the power of Guardant Health's InfinityAI platform and real-world dat

benzinga.com
Guardant Health Highlights Poll Results Showing Overwhelming Majority Of Respondents Believe Colorec

The survey showed an overwhelming majority of Americans of screening-eligible age (92%) believe that

benzinga.com
Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $130

Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight an

benzinga.com
Leerink Partners Maintains Outperform on Guardant Health, Raises Price Target to $180

Leerink Partners analyst Puneet Souda maintains Guardant Health (NASDAQ:GH) with a Outperform and

benzinga.com
Citigroup Maintains Buy on Guardant Health, Raises Price Target to $150

Citigroup analyst Patrick Donnelly maintains Guardant Health (NASDAQ:GH) with a Buy and raises th

benzinga.com
Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $135

Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and raises

benzinga.com
JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $130

JP Morgan analyst Casey Woodring maintains Guardant Health (NASDAQ:GH) with a Overweight and rais

benzinga.com
TD Cowen Maintains Buy on Guardant Health, Raises Price Target to $135

TD Cowen analyst Dan Brennan maintains Guardant Health (NASDAQ:GH) with a Buy and raises the pric

benzinga.com
Wells Fargo Maintains Overweight on Guardant Health, Raises Price Target to $125

Wells Fargo analyst Brandon Couillard maintains Guardant Health (NASDAQ:GH) with a Overweight and

benzinga.com
Stifel Maintains Buy on Guardant Health, Raises Price Target to $130

Stifel analyst Daniel Arias maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price

benzinga.com
Evercore ISI Group Maintains In-Line on Guardant Health, Raises Price Target to $110

Evercore ISI Group analyst Daniel Markowitz maintains Guardant Health (NASDAQ:GH) with a In-Line

benzinga.com
BTIG Maintains Buy on Guardant Health, Lowers Price Target to $145

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and lowers the price t

benzinga.com
Guardant Health Q4 Adj. EPS $(0.50) Beats $(0.69) Estimate, Sales $281.266M Beat $271.011M Estimate

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.50) per share which beat the analyst co

Earnings Scheduled For February 19, 2026
benzinga.com
Earnings Scheduled For February 19, 2026

benzinga.com
Baird Initiates Coverage On Guardant Health with Outperform Rating, Announces Price Target of $120

Baird analyst Catherine Schulte initiates coverage on Guardant Health (NASDAQ:GH) with a Outperfo

A Congress Member Sold Up To $125K In McDonald's Stock: Here's What You Need To Know
benzinga.com
A Congress Member Sold Up To $125K In McDonald's Stock: Here's What You Need To Know

benzinga.com
Guardant Health Announces Publication Of Study To Date Evaluating Circulating Tumor DNA For MRD Dete

Data published in Journal of Clinical Oncology supports routine use of circulating tumor DNA (ctDNA)